<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2211">
  <stage>Registered</stage>
  <submitdate>10/06/2008</submitdate>
  <approvaldate>10/06/2008</approvaldate>
  <nctid>NCT00809068</nctid>
  <trial_identification>
    <studytitle>High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone</studytitle>
    <scientifictitle>Effects of Tibolone and PPARa-agonist on HDL Metabolism in Postmenopausal Women</scientifictitle>
    <utrn />
    <trialacronym>TibFen</trialacronym>
    <secondaryid>SCGH Research Grant</secondaryid>
    <secondaryid>ID: 2005-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HDL Cholesterol</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - fenofibrate and tibolone
Treatment: drugs - tibolone

Active Comparator: 1 - fenofibrate and tibolone

Sham Comparator: 2 - tibolone


Treatment: drugs: fenofibrate and tibolone
fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks

Treatment: drugs: tibolone
tibolone 2.5 mg daily 23 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HDL subpopulation analysis</outcome>
      <timepoint>August 2009</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Increase in HDL subpopulations</outcome>
      <timepoint>December 2009</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Post-menopausal women

          -  More than 6 months of amenorrhoea

          -  Raised FSH and low oestradiol level

          -  If hysterectomised, raised FSH and low oestradiol level</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Diabetes

          -  Renal failure

          -  Proteinuria

          -  High alcohol intake

          -  Regular endurance exercise

          -  Active weight loss of dieting

          -  Smokers

          -  Agents known to influence lipid metabolism

          -  Major systemic illness

          -  Intolerance to tibolone and fenofibrate

          -  Cholelithiasis

          -  CK and ALT &gt; 2ULN

          -  Bleeding disorders

          -  Peptic ulcer disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Keogh Institute for Medical Research, 'A' Block 3rd Floor, QE II Medical Centre, Nedlands - Perth</hospital>
    <postcode>6009 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Keogh Institute for Medical Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Tibolone (Livial) has been shown in previous studies to lower HDL cholesterol by up to 40%.

      This study aims to study the effects of fenofibrate on HDL and subfractions in women taking
      tibolone.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00809068</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bronwyn G Stuckey, MBBS FRACP</name>
      <address>Keogh Institute for Medical Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>